BiotechTube

Trastuzumab Deruxtecan (T-DXd) monotherapy + T-DXd, Durvalumab and Capecitabine Combination

Phase 2Recruiting
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Gastric Adenocarcinoma

Conditions

Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

Trial Timeline

Jan 31, 2022 → Mar 31, 2029

NCT ID
NCT05034887

About Trastuzumab Deruxtecan (T-DXd) monotherapy + T-DXd, Durvalumab and Capecitabine Combination

Trastuzumab Deruxtecan (T-DXd) monotherapy + T-DXd, Durvalumab and Capecitabine Combination is a phase 2 stage product being developed by Daiichi Sankyo for Gastric Adenocarcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05034887. Target conditions include Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05034887Phase 2Recruiting

Competing Products

20 competing products in Gastric Adenocarcinoma

See all competitors
ProductCompanyStageHype Score
pemetrexed + cisplatinEli LillyPhase 1/2
41
InfigratinibLianBioPhase 2
44
InfigratinibLianBioPhase 2
44
Ramucirumab + MEDI4736Eli LillyPhase 1
33
RamucirumabEli LillyPhase 2
52
Trastuzumab + Capecitabine + CisplatinCelltrionPhase 2
52
Trastuzumab + Fluorouracil + Cisplatin + CapecitabineChugai PharmaceuticalPhase 3
77
Fluorouracil (5-FU) + Capecitabine + Durvalumab + Oxaliplatin + Trastuzumab + Trastuzumab deruxtecan + Cisplatin + Pembrolizumab + Volrustomig + RilvegostomigDaiichi SankyoPhase 2
52
Trastuzumab DeruxtecanDaiichi SankyoPhase 2
52
Trastuzumab deruxtecan + Ramucirumab + PaclitaxelDaiichi SankyoPhase 3
77
Trastuzumab deruxtecanDaiichi SankyoPre-clinical
23
Trastuzumab deruxtecan + BevacizumabDaiichi SankyoPhase 2
52
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Trastuzumab deruxtecan (T-DXd)Daiichi SankyoPre-clinical
23
DS-8201aDaiichi SankyoPhase 1
33
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Irinotecan + NimotuzumabDaiichi SankyoPhase 3
77
Trastuzumab Deruxtecan + pembrolizumab + Trastuzumab + ChemotherapyDaiichi SankyoPhase 3
77
Trastuzumab deruxtecan + 5FU/LV + Trastuzumab deruxtecan + FLODaiichi SankyoPhase 1/2
41
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved
85
OAC aloneApproved
85
olmesartan medoxomil + Placebo + losartan potassiumApproved
85
Prasugrel + ClopidogrelApproved
85
Diet+pravastatinApproved
85